Concepts (167)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 12 | 2017 | 397 | 1.960 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 3 | 2019 | 120 | 1.170 |
Why?
|
| Anti-Asthmatic Agents | 5 | 2013 | 71 | 0.740 |
Why?
|
| Muscle, Smooth | 7 | 2010 | 73 | 0.600 |
Why?
|
| Exercise Therapy | 1 | 2019 | 229 | 0.580 |
Why?
|
| Trachea | 5 | 2010 | 55 | 0.450 |
Why?
|
| Pharmacogenetics | 1 | 2010 | 35 | 0.370 |
Why?
|
| Dinoprostone | 2 | 2010 | 37 | 0.370 |
Why?
|
| Interleukin-1 | 1 | 2005 | 33 | 0.270 |
Why?
|
| Patient Care | 1 | 2005 | 33 | 0.260 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 3 | 2010 | 18 | 0.260 |
Why?
|
| Bronchoscopy | 3 | 2017 | 56 | 0.260 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2012 | 148 | 0.250 |
Why?
|
| Humans | 23 | 2019 | 29123 | 0.250 |
Why?
|
| Clinical Trials as Topic | 3 | 2010 | 298 | 0.240 |
Why?
|
| Lung | 1 | 2005 | 233 | 0.230 |
Why?
|
| Respiratory Function Tests | 5 | 2019 | 111 | 0.230 |
Why?
|
| Bronchodilator Agents | 3 | 2013 | 82 | 0.220 |
Why?
|
| Scopolamine Derivatives | 2 | 2013 | 9 | 0.210 |
Why?
|
| Protein Kinase C | 3 | 2007 | 37 | 0.210 |
Why?
|
| Severity of Illness Index | 3 | 2017 | 863 | 0.210 |
Why?
|
| Glucocorticoids | 3 | 2010 | 149 | 0.180 |
Why?
|
| Membrane Proteins | 3 | 2007 | 256 | 0.170 |
Why?
|
| Myocytes, Smooth Muscle | 2 | 2010 | 74 | 0.170 |
Why?
|
| Quercetin | 1 | 2019 | 8 | 0.170 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2019 | 6 | 0.170 |
Why?
|
| Eosinophils | 2 | 2013 | 48 | 0.170 |
Why?
|
| Ambulatory Care | 1 | 2019 | 96 | 0.160 |
Why?
|
| Albuterol | 3 | 2013 | 40 | 0.160 |
Why?
|
| Exercise Tolerance | 1 | 2019 | 110 | 0.160 |
Why?
|
| Self Care | 1 | 2019 | 137 | 0.160 |
Why?
|
| Patient Selection | 1 | 2019 | 257 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 3 | 2012 | 374 | 0.150 |
Why?
|
| Cells, Cultured | 6 | 2010 | 799 | 0.150 |
Why?
|
| Receptors, Leukotriene | 2 | 2007 | 4 | 0.140 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2010 | 200 | 0.140 |
Why?
|
| Cytokines | 2 | 2007 | 243 | 0.130 |
Why?
|
| Sputum | 1 | 2013 | 33 | 0.110 |
Why?
|
| Neutrophils | 1 | 2013 | 102 | 0.110 |
Why?
|
| Spirometry | 1 | 2011 | 32 | 0.100 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2008 | 89 | 0.100 |
Why?
|
| T-Lymphocytes | 1 | 2011 | 114 | 0.100 |
Why?
|
| Cell Proliferation | 2 | 2010 | 573 | 0.100 |
Why?
|
| Cholinergic Antagonists | 1 | 2010 | 12 | 0.100 |
Why?
|
| Disease Management | 1 | 2011 | 114 | 0.100 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 2010 | 4 | 0.100 |
Why?
|
| Interleukin-5 | 1 | 2010 | 7 | 0.090 |
Why?
|
| Th2 Cells | 1 | 2010 | 14 | 0.090 |
Why?
|
| Proton Pump Inhibitors | 1 | 2010 | 11 | 0.090 |
Why?
|
| Disease Susceptibility | 1 | 2010 | 53 | 0.090 |
Why?
|
| Immunomodulation | 1 | 2010 | 30 | 0.090 |
Why?
|
| Gastroesophageal Reflux | 1 | 2010 | 25 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2010 | 37 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2010 | 44 | 0.090 |
Why?
|
| Disease Outbreaks | 1 | 2010 | 35 | 0.090 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2010 | 49 | 0.090 |
Why?
|
| Disease Progression | 1 | 2011 | 572 | 0.090 |
Why?
|
| Influenza Vaccines | 1 | 2010 | 78 | 0.090 |
Why?
|
| Androstadienes | 1 | 2008 | 17 | 0.080 |
Why?
|
| G-Protein-Coupled Receptor Kinase 3 | 1 | 2008 | 2 | 0.080 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2008 | 3 | 0.080 |
Why?
|
| G-Protein-Coupled Receptor Kinase 2 | 1 | 2008 | 3 | 0.080 |
Why?
|
| Vitamin D | 1 | 2010 | 172 | 0.080 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2008 | 50 | 0.080 |
Why?
|
| Influenza, Human | 1 | 2010 | 122 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 196 | 0.080 |
Why?
|
| Mitogens | 1 | 2007 | 2 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 285 | 0.080 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2007 | 39 | 0.080 |
Why?
|
| Signal Transduction | 2 | 2008 | 666 | 0.080 |
Why?
|
| Muscle Contraction | 1 | 2007 | 114 | 0.070 |
Why?
|
| Adult | 6 | 2017 | 8426 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2011 | 1306 | 0.070 |
Why?
|
| Phospholipases A2 | 1 | 2005 | 22 | 0.070 |
Why?
|
| Microsomes | 1 | 2005 | 14 | 0.070 |
Why?
|
| Cytosol | 1 | 2005 | 25 | 0.070 |
Why?
|
| Receptors, Prostaglandin E | 1 | 2005 | 4 | 0.070 |
Why?
|
| Phospholipases A | 1 | 2005 | 28 | 0.070 |
Why?
|
| Cyclooxygenase 1 | 1 | 2005 | 23 | 0.070 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 32 | 0.070 |
Why?
|
| Respiratory Mucosa | 1 | 2005 | 10 | 0.070 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2005 | 36 | 0.070 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 2005 | 32 | 0.070 |
Why?
|
| Cyclooxygenase 2 | 1 | 2005 | 50 | 0.070 |
Why?
|
| Education, Continuing | 1 | 2005 | 5 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 162 | 0.060 |
Why?
|
| Male | 7 | 2019 | 17815 | 0.060 |
Why?
|
| Female | 7 | 2019 | 18173 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 273 | 0.060 |
Why?
|
| Middle Aged | 5 | 2019 | 10834 | 0.060 |
Why?
|
| Transfection | 3 | 2010 | 192 | 0.060 |
Why?
|
| Allergens | 1 | 2002 | 16 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2002 | 45 | 0.060 |
Why?
|
| Membrane Glycoproteins | 1 | 2002 | 97 | 0.050 |
Why?
|
| Forced Expiratory Volume | 2 | 2013 | 112 | 0.050 |
Why?
|
| Cross-Over Studies | 2 | 2013 | 94 | 0.050 |
Why?
|
| Inflammation | 1 | 2005 | 508 | 0.050 |
Why?
|
| Animals | 4 | 2007 | 7300 | 0.050 |
Why?
|
| Administration, Inhalation | 2 | 2012 | 92 | 0.050 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2017 | 67 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2012 | 503 | 0.050 |
Why?
|
| Epidermal Growth Factor | 2 | 2010 | 21 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2019 | 3101 | 0.040 |
Why?
|
| Interleukin-1beta | 2 | 2008 | 41 | 0.040 |
Why?
|
| Green Fluorescent Proteins | 2 | 2010 | 71 | 0.040 |
Why?
|
| Enzyme Activation | 2 | 2010 | 126 | 0.040 |
Why?
|
| Bronchi | 2 | 2011 | 41 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2019 | 469 | 0.040 |
Why?
|
| Prednisolone | 1 | 2017 | 10 | 0.040 |
Why?
|
| Patient Compliance | 1 | 2019 | 208 | 0.040 |
Why?
|
| Amino Acid Sequence | 2 | 2005 | 280 | 0.030 |
Why?
|
| Time Factors | 2 | 2010 | 2001 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2013 | 55 | 0.030 |
Why?
|
| Immunoglobulin E | 1 | 2013 | 47 | 0.030 |
Why?
|
| Quality of Life | 1 | 2019 | 816 | 0.030 |
Why?
|
| ROC Curve | 1 | 2013 | 149 | 0.030 |
Why?
|
| Breath Tests | 1 | 2012 | 17 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2012 | 159 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2012 | 116 | 0.030 |
Why?
|
| Bronchial Provocation Tests | 1 | 2011 | 14 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 3719 | 0.020 |
Why?
|
| Beclomethasone | 1 | 2010 | 8 | 0.020 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 2010 | 15 | 0.020 |
Why?
|
| Isoproterenol | 1 | 2010 | 18 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2010 | 50 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2010 | 65 | 0.020 |
Why?
|
| Mice | 2 | 2007 | 2371 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2010 | 225 | 0.020 |
Why?
|
| Prognosis | 1 | 2013 | 1362 | 0.020 |
Why?
|
| Autocrine Communication | 1 | 2008 | 5 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2008 | 128 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 2008 | 40 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 155 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 109 | 0.020 |
Why?
|
| Phosphatidylinositols | 1 | 2007 | 2 | 0.020 |
Why?
|
| Leukotrienes | 1 | 2007 | 4 | 0.020 |
Why?
|
| Inhalation | 1 | 2007 | 8 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2008 | 320 | 0.020 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2007 | 18 | 0.020 |
Why?
|
| Chemokine CCL2 | 1 | 2007 | 47 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 172 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2008 | 514 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2007 | 249 | 0.020 |
Why?
|
| Monocytes | 1 | 2007 | 119 | 0.020 |
Why?
|
| Aged | 1 | 2019 | 9492 | 0.020 |
Why?
|
| Calcium | 1 | 2007 | 297 | 0.020 |
Why?
|
| Leukotriene D4 | 1 | 2004 | 2 | 0.020 |
Why?
|
| COS Cells | 1 | 2004 | 28 | 0.020 |
Why?
|
| Open Reading Frames | 1 | 2004 | 18 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2004 | 85 | 0.020 |
Why?
|
| Protein Transport | 1 | 2004 | 74 | 0.020 |
Why?
|
| Kinetics | 1 | 2004 | 205 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2004 | 178 | 0.020 |
Why?
|
| Young Adult | 1 | 2011 | 2402 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 350 | 0.020 |
Why?
|
| Cell Line | 1 | 2004 | 450 | 0.010 |
Why?
|
| Adolescent | 1 | 2011 | 3255 | 0.010 |
Why?
|
| Tumor Necrosis Factor Decoy Receptors | 1 | 2002 | 3 | 0.010 |
Why?
|
| Immune Sera | 1 | 2002 | 9 | 0.010 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2002 | 6 | 0.010 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2002 | 10 | 0.010 |
Why?
|
| Solubility | 1 | 2002 | 38 | 0.010 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2002 | 33 | 0.010 |
Why?
|
| Cell Survival | 1 | 2002 | 272 | 0.010 |
Why?
|
| Cell Movement | 1 | 2002 | 161 | 0.010 |
Why?
|
| Apoptosis | 1 | 2002 | 337 | 0.010 |
Why?
|
| Kidney | 1 | 2004 | 486 | 0.010 |
Why?
|